See the articles below for the latest on the 2023 landscape:
- A world tour of Big Pharma: Mapping the HQs of the top 50 companies
- Best-selling pharmaceuticals reveal a shift in pharma landscape
- Big Pharma shakeup: Merck & Co. is the new top dog of fiscal year 2023
- When size doesn’t matter: How Lilly and Novo Nordisk are outperforming pharma giants in value creation
- With prices topping $4 million, high stakes define cell and gene therapy landscape
- In fiscal year 2023, Roche and Novartis led the pack in drug pipeline scale
- Top pharma companies ranked by fiscal year 2023 R&D spend
- Are Big Pharma giants getting the right ROI on their R&D investments? A visual exploration based on fiscal year 2023 data
- Best-selling pharmaceuticals of fiscal year 2023 reveal a shift in pharma landscape
Pharma 50: Fiscal year 2022 analysis
Our third-annual Pharma 50 feature ranks the world’s largest pharma companies using revenue data from fiscal year 2022 annual reports. These industry leaders have shown resilience and innovation amidst the challenges of the ongoing pandemic.
Compare this year’s rankings with our 2022 Pharma 50 report (based on fiscal year 2021 data) to see how the landscape has evolved. For a comprehensive analysis of all 50 companies, download our PDF report.
- Top pharma companies ranked by fiscal year 2022 R&D spend
- Top 10 pharma employers based on fiscal year 2022 data
- Discover the 25 top pharma employers based on fiscal year 2022 data
- Top 100 cell and gene therapy companies to watch in fiscal year 2022
- Prominent cell and gene therapy vendors in fiscal year 2022
- 10 pioneering companies implementing AI in drug discovery, development and beyond in fiscal year 2022